Cargando…
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
BACKGROUND: Platinum-based chemoradiotherapy is the standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC). However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC following platinum-based chemoradiotherapy. This study aimed to evaluat...
Autores principales: | Miyawaki, Eriko, Kenmotsu, Hirotsugu, Shintani, Yasushi, Sekine, Ikuo, Shukuya, Takehito, Takayama, Koichi, Inoue, Akira, Okamoto, Isamu, Kiura, Katsuyuki, Takahashi, Kazuhisa, Yamamoto, Nobuyuki, Kawaguchi, Tomoya, Miyaoka, Etsuo, Yoshino, Ichiro, Date, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962203/ https://www.ncbi.nlm.nih.gov/pubmed/35351059 http://dx.doi.org/10.1186/s12885-022-09441-3 |
Ejemplares similares
-
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
por: Shukuya, Takehito, et al.
Publicado: (2023) -
A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients
por: Sekine, Ikuo, et al.
Publicado: (2020) -
Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015) -
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society
por: Ozawa, Yuichi, et al.
Publicado: (2022) -
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)